Indeed, the promotion of Bcr-Abl-dependent leukemias by E2F mutation is not due to cell autonomous contributions of E2f1/E2f2 loss, as E2f1+2+ competitors virtually eliminate leukemias resulting from Bcr-Abl expression in DKO progenitors. The gene discussed is E2F2; the disease is leukemia.